V. Gusarova

发表

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S]

Jonathan C. Cohen, H. Hobbs, J. Gromada, 2015, Journal of Lipid Research.

ANGPTL8/Betatrophin Does Not Control Pancreatic Beta Cell Expansion

Jonathan C. Cohen, H. Hobbs, S. Bonner-Weir, 2014, Cell.

Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis

Jonathan C. Cohen, H. Hobbs, J. Gromada, 2013, Proceedings of the National Academy of Sciences.

ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S]

Jonathan C. Cohen, H. Hobbs, A. Murphy, 2017, Journal of Lipid Research.

ANGPTL8 Blockade With a Monoclonal Antibody Promotes Triglyceride Clearance, Energy Expenditure, and Weight Loss in Mice

Jonathan C. Cohen, H. Hobbs, A. Murphy, 2017, Endocrinology.

Hepatic ANGPTL3 regulates adipose tissue energy homeostasis

Jonathan C. Cohen, H. Hobbs, J. Gromada, 2015, Proceedings of the National Academy of Sciences.

Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates

A. Murphy, H. Okamoto, G. Yancopoulos, 2012 .

Reduction of LDL cholesterol by a monoclonal

H. Okamoto, Victor G. Howard, V. Gusarova, 2012 .

Increased thermogenesis by a noncanonical pathway in ANGPTL3/8-deficient mice

Jonathan C. Cohen, H. Hobbs, J. Gromada, 2018, Proceedings of the National Academy of Sciences.

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice[S]

J. Jukema, J. Gromada, E. Pieterman, 2019, Journal of Lipid Research.

Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

Jonathan C. Cohen, H. Hobbs, A. Murphy, 2020, Journal of Lipid Research.

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

J. Jukema, W. Sasiela, U. Schwahn, 2014, Journal of Lipid Research.

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.

D. Gaudet, P. Shah, D. Brisson, 2017, The New England journal of medicine.

Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance

Jonathan C. Cohen, H. Hobbs, A. Murphy, 2020 .

Germline Mutations in CIDEB and Protection against Liver Disease.

Johnathon R. Walls, G. Abecasis, H. Kang, 2022, The New England journal of medicine.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

N. Stahl, C. Kyratsous, V. Gusarova, 2016, PloS one.

Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes

Johnathon R. Walls, Mary E. Haas, R. Collins, 2022, Nature Communications.

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Tanya M. Teslovich, D. Ledbetter, S. McCarthy, 2017, The New England journal of medicine.

Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.

W. Sasiela, U. Schwahn, D. Blom, 2014, Journal of the American College of Cardiology.

Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes

Alexander E. Lopez, David L. Birtwell, Tanya M. Teslovich, 2018, Nature Communications.

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.

Alexander E. Lopez, D. Ledbetter, F. Dewey, 2016, The New England journal of medicine.

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys1[S]

Jonathan C. Cohen, H. Hobbs, A. Murphy, 2015, Journal of Lipid Research.

Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression

K. Moore, S. Ramsey, P. Loke, 2017, The Journal of clinical investigation.

Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice

J. Jukema, W. Sasiela, U. Schwahn, 2014 .

Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8

Jonathan C. Cohen, H. Hobbs, V. Gusarova, 2021, The Journal of clinical endocrinology and metabolism.

ANGPTL8 has both endocrine and autocrine effects on substrate utilization

Jonathan C. Cohen, H. Hobbs, S. Banfi, 2020, JCI insight.

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice

J. Jukema, J. Gromada, E. Pieterman, 2019 .

Inactivating Variants in ANGPTL 4 and Risk of Coronary Artery Disease

Alexander E. Lopez, D. Ledbetter, F. Dewey, 2016 .

Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice

G. Atwal, A. Murphy, G. Yancopoulos, 2023, Proceedings of the National Academy of Sciences of the United States of America.